Tumor microenvironment in T-Cell lymphomas

N. Nora Bennani, Stephen Maxted Ansell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

T-cell lymphomas (TCL) are uncommon non-Hodgkin lymphomas that often have an aggressive clinical course. Patients typically have limited treatment options upon relapse and a dismal prognosis after progression despite newly approved therapies. New therapeutic approaches for these orphan diseases are very much needed and a greater understanding of the role of nonmalignant immune cells in the tumor microenvironment may allow for an improved antitumor immune response. The tumor microenvironment is a key component in tumor evasion and typically results in an ineffective T-cell response to the tumor cells despite a significant inflammatory response. A better understanding of the tumor microenvironment therefore, in an effort to overcome the barriers to an effective immune response, would help in developing novel therapeutic approaches to treat and improve outcomes of these diseases. Immune checkpoint blockade to reinvigorate suppressed T-cell, or modulation of the CD47-SIRPalpha axis to promote macrophage phagocytosis, would be such targets. However, whether modulating the immune response using each pathway alone or whether a combination approach is necessary has yet to be determined.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages69-82
Number of pages14
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume176
ISSN (Print)0927-3042

Fingerprint

Tumor Microenvironment
T-Cell Lymphoma
T-Lymphocytes
Therapeutics
Rare Diseases
Phagocytosis
Non-Hodgkin's Lymphoma
Neoplasms
Macrophages
Recurrence

Keywords

  • CD47-SIRPalpha axis
  • Checkpoint blockade
  • Helper T-cells
  • Immunotherapy
  • Regulatory T-cells
  • T-cell lymphoma
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bennani, N. N., & Ansell, S. M. (2019). Tumor microenvironment in T-Cell lymphomas. In Cancer Treatment and Research (pp. 69-82). (Cancer Treatment and Research; Vol. 176). Springer International Publishing. https://doi.org/10.1007/978-3-319-99716-2_3

Tumor microenvironment in T-Cell lymphomas. / Bennani, N. Nora; Ansell, Stephen Maxted.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 69-82 (Cancer Treatment and Research; Vol. 176).

Research output: Chapter in Book/Report/Conference proceedingChapter

Bennani, NN & Ansell, SM 2019, Tumor microenvironment in T-Cell lymphomas. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 176, Springer International Publishing, pp. 69-82. https://doi.org/10.1007/978-3-319-99716-2_3
Bennani NN, Ansell SM. Tumor microenvironment in T-Cell lymphomas. In Cancer Treatment and Research. Springer International Publishing. 2019. p. 69-82. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-99716-2_3
Bennani, N. Nora ; Ansell, Stephen Maxted. / Tumor microenvironment in T-Cell lymphomas. Cancer Treatment and Research. Springer International Publishing, 2019. pp. 69-82 (Cancer Treatment and Research).
@inbook{334edc2063fc409a84f510f916b96712,
title = "Tumor microenvironment in T-Cell lymphomas",
abstract = "T-cell lymphomas (TCL) are uncommon non-Hodgkin lymphomas that often have an aggressive clinical course. Patients typically have limited treatment options upon relapse and a dismal prognosis after progression despite newly approved therapies. New therapeutic approaches for these orphan diseases are very much needed and a greater understanding of the role of nonmalignant immune cells in the tumor microenvironment may allow for an improved antitumor immune response. The tumor microenvironment is a key component in tumor evasion and typically results in an ineffective T-cell response to the tumor cells despite a significant inflammatory response. A better understanding of the tumor microenvironment therefore, in an effort to overcome the barriers to an effective immune response, would help in developing novel therapeutic approaches to treat and improve outcomes of these diseases. Immune checkpoint blockade to reinvigorate suppressed T-cell, or modulation of the CD47-SIRPalpha axis to promote macrophage phagocytosis, would be such targets. However, whether modulating the immune response using each pathway alone or whether a combination approach is necessary has yet to be determined.",
keywords = "CD47-SIRPalpha axis, Checkpoint blockade, Helper T-cells, Immunotherapy, Regulatory T-cells, T-cell lymphoma, Tumor microenvironment",
author = "Bennani, {N. Nora} and Ansell, {Stephen Maxted}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-319-99716-2_3",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "69--82",
booktitle = "Cancer Treatment and Research",

}

TY - CHAP

T1 - Tumor microenvironment in T-Cell lymphomas

AU - Bennani, N. Nora

AU - Ansell, Stephen Maxted

PY - 2019/1/1

Y1 - 2019/1/1

N2 - T-cell lymphomas (TCL) are uncommon non-Hodgkin lymphomas that often have an aggressive clinical course. Patients typically have limited treatment options upon relapse and a dismal prognosis after progression despite newly approved therapies. New therapeutic approaches for these orphan diseases are very much needed and a greater understanding of the role of nonmalignant immune cells in the tumor microenvironment may allow for an improved antitumor immune response. The tumor microenvironment is a key component in tumor evasion and typically results in an ineffective T-cell response to the tumor cells despite a significant inflammatory response. A better understanding of the tumor microenvironment therefore, in an effort to overcome the barriers to an effective immune response, would help in developing novel therapeutic approaches to treat and improve outcomes of these diseases. Immune checkpoint blockade to reinvigorate suppressed T-cell, or modulation of the CD47-SIRPalpha axis to promote macrophage phagocytosis, would be such targets. However, whether modulating the immune response using each pathway alone or whether a combination approach is necessary has yet to be determined.

AB - T-cell lymphomas (TCL) are uncommon non-Hodgkin lymphomas that often have an aggressive clinical course. Patients typically have limited treatment options upon relapse and a dismal prognosis after progression despite newly approved therapies. New therapeutic approaches for these orphan diseases are very much needed and a greater understanding of the role of nonmalignant immune cells in the tumor microenvironment may allow for an improved antitumor immune response. The tumor microenvironment is a key component in tumor evasion and typically results in an ineffective T-cell response to the tumor cells despite a significant inflammatory response. A better understanding of the tumor microenvironment therefore, in an effort to overcome the barriers to an effective immune response, would help in developing novel therapeutic approaches to treat and improve outcomes of these diseases. Immune checkpoint blockade to reinvigorate suppressed T-cell, or modulation of the CD47-SIRPalpha axis to promote macrophage phagocytosis, would be such targets. However, whether modulating the immune response using each pathway alone or whether a combination approach is necessary has yet to be determined.

KW - CD47-SIRPalpha axis

KW - Checkpoint blockade

KW - Helper T-cells

KW - Immunotherapy

KW - Regulatory T-cells

KW - T-cell lymphoma

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85059260926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059260926&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-99716-2_3

DO - 10.1007/978-3-319-99716-2_3

M3 - Chapter

T3 - Cancer Treatment and Research

SP - 69

EP - 82

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -